Philip J Peters1, Emily Westheimer2, Stephanie Cohen3, Lisa B Hightow-Weidman4, Nicholas Moss5, Benjamin Tsoi2, Laura Hall6, Charles Fann3, Demetre C Daskalakis7, Steve Beagle4, Pragna Patel1, Asa Radix8, Evelyn Foust9, Robert P Kohn3, Jenni Marmorino4, Mark Pandori5, Jie Fu2, Taraz Samandari1, Cynthia L Gay4. 1. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. New York City Department of Health and Mental Hygiene, New York City. 3. San Francisco Department of Public Health, San Francisco, California. 4. University of North Carolina at Chapel Hill, Chapel Hill. 5. San Francisco Department of Public Health, San Francisco, California5Alameda County Department of Public Health, Oakland, California. 6. ICF International, Atlanta, Georgia. 7. New York City Department of Health and Mental Hygiene, New York City7Mount Sinai School of Medicine, New York City, New York. 8. Callen Lorde Community Health Center, New York City, New York. 9. North Carolina Department of Public Health, Raleigh.
Abstract
IMPORTANCE: Although acute HIV infection contributes disproportionately to onward HIV transmission, HIV testing has not routinely included screening for acute HIV infection. OBJECTIVE: To evaluate the performance of an HIV antigen/antibody (Ag/Ab) combination assay to detect acute HIV infection compared with pooled HIV RNA testing. DESIGN, SETTING, AND PARTICIPANTS: Multisite, prospective, within-individual comparison study conducted between September 2011 and October 2013 in 7 sexually transmitted infection clinics and 5 community-based programs in New York, California, and North Carolina. Participants were 12 years or older and seeking HIV testing, without known HIV infection. EXPOSURES: All participants with a negative rapid HIV test result were screened for acute HIV infection with an HIV Ag/Ab combination assay (index test) and pooled human immunodeficiency virus 1 (HIV-1) RNA testing. HIV RNA testing was the reference standard, with positive reference standard result defined as detectable HIV-1 RNA on an individual RNA test. MAIN OUTCOMES AND MEASURES: Number and proportion with acute HIV infections detected. RESULTS: Among 86,836 participants with complete test results (median age, 29 years; 75.0% men; 51.8% men who have sex with men), established HIV infection was diagnosed in 1158 participants (1.33%) and acute HIV infection was diagnosed in 168 participants (0.19%). Acute HIV infection was detected in 134 participants with HIV Ag/Ab combination testing (0.15% [95% CI, 0.13%-0.18%]; sensitivity, 79.8% [95% CI, 72.9%-85.6%]; specificity, 99.9% [95% CI, 99.9%-99.9%]; positive predictive value, 59.0% [95% CI, 52.3%-65.5%]) and in 164 participants with pooled HIV RNA testing (0.19% [95% CI, 0.16%-0.22%]; sensitivity, 97.6% [95% CI, 94.0%-99.4%]; specificity, 100% [95% CI, 100%-100%]; positive predictive value, 96.5% [95% CI, 92.5%-98.7%]; sensitivity comparison, P < .001). Overall HIV Ag/Ab combination testing detected 82% of acute HIV infections detectable by pooled HIV RNA testing. Compared with rapid HIV testing alone, HIV Ag/Ab combination testing increased the relative HIV diagnostic yield (both established and acute HIV infections) by 10.4% (95% CI, 8.8%-12.2%) and pooled HIV RNA testing increased the relative HIV diagnostic yield by 12.4% (95% CI, 10.7%-14.3%). CONCLUSIONS AND RELEVANCE: In a high-prevalence population, HIV screening using an HIV Ag/Ab combination assay following a negative rapid test detected 82% of acute HIV infections detectable by pooled HIV RNA testing, with a positive predictive value of 59%. Further research is needed to evaluate this strategy in lower-prevalence populations and in persons using preexposure prophylaxis for HIV prevention.
IMPORTANCE: Although acute HIV infection contributes disproportionately to onward HIV transmission, HIV testing has not routinely included screening for acute HIV infection. OBJECTIVE: To evaluate the performance of an HIV antigen/antibody (Ag/Ab) combination assay to detect acute HIV infection compared with pooled HIV RNA testing. DESIGN, SETTING, AND PARTICIPANTS: Multisite, prospective, within-individual comparison study conducted between September 2011 and October 2013 in 7 sexually transmitted infection clinics and 5 community-based programs in New York, California, and North Carolina. Participants were 12 years or older and seeking HIV testing, without known HIV infection. EXPOSURES: All participants with a negative rapid HIV test result were screened for acute HIV infection with an HIV Ag/Ab combination assay (index test) and pooled human immunodeficiency virus 1 (HIV-1) RNA testing. HIV RNA testing was the reference standard, with positive reference standard result defined as detectable HIV-1 RNA on an individual RNA test. MAIN OUTCOMES AND MEASURES: Number and proportion with acute HIV infections detected. RESULTS: Among 86,836 participants with complete test results (median age, 29 years; 75.0% men; 51.8% men who have sex with men), established HIV infection was diagnosed in 1158 participants (1.33%) and acute HIV infection was diagnosed in 168 participants (0.19%). Acute HIV infection was detected in 134 participants with HIV Ag/Ab combination testing (0.15% [95% CI, 0.13%-0.18%]; sensitivity, 79.8% [95% CI, 72.9%-85.6%]; specificity, 99.9% [95% CI, 99.9%-99.9%]; positive predictive value, 59.0% [95% CI, 52.3%-65.5%]) and in 164 participants with pooled HIV RNA testing (0.19% [95% CI, 0.16%-0.22%]; sensitivity, 97.6% [95% CI, 94.0%-99.4%]; specificity, 100% [95% CI, 100%-100%]; positive predictive value, 96.5% [95% CI, 92.5%-98.7%]; sensitivity comparison, P < .001). Overall HIV Ag/Ab combination testing detected 82% of acute HIV infections detectable by pooled HIV RNA testing. Compared with rapid HIV testing alone, HIV Ag/Ab combination testing increased the relative HIV diagnostic yield (both established and acute HIV infections) by 10.4% (95% CI, 8.8%-12.2%) and pooled HIV RNA testing increased the relative HIV diagnostic yield by 12.4% (95% CI, 10.7%-14.3%). CONCLUSIONS AND RELEVANCE: In a high-prevalence population, HIV screening using an HIV Ag/Ab combination assay following a negative rapid test detected 82% of acute HIV infections detectable by pooled HIV RNA testing, with a positive predictive value of 59%. Further research is needed to evaluate this strategy in lower-prevalence populations and in persons using preexposure prophylaxis for HIV prevention.
Authors: Dvora Joseph Davey; Matthew Beymer; Chelsea P Roberts; Robert K Bolan; Jeffrey D Klausner Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Kara G Marson; Robert Marlin; Phong Pham; Stephanie E Cohen; Diane Jones; Marguerite Roemer; Philip J Peters; Barbara Haller; Christopher D Pilcher Journal: J Clin Virol Date: 2017-04-07 Impact factor: 3.168
Authors: Ruth H Keogh; Pamela A Shaw; Paul Gustafson; Raymond J Carroll; Veronika Deffner; Kevin W Dodd; Helmut Küchenhoff; Janet A Tooze; Michael P Wallace; Victor Kipnis; Laurence S Freedman Journal: Stat Med Date: 2020-04-03 Impact factor: 2.373
Authors: Eleanor R Gray; Robert Bain; Olivia Varsaneux; Rosanna W Peeling; Molly M Stevens; Rachel A McKendry Journal: AIDS Date: 2018-09-24 Impact factor: 4.177
Authors: Sarah E Rutstein; Jintanat Ananworanich; Sarah Fidler; Cheryl Johnson; Eduard J Sanders; Omar Sued; Asier Saez-Cirion; Christopher D Pilcher; Christophe Fraser; Myron S Cohen; Marco Vitoria; Meg Doherty; Joseph D Tucker Journal: J Int AIDS Soc Date: 2017-06-28 Impact factor: 5.396
Authors: Maartje Dijkstra; Khamisi Mohamed; Alex Kigoro; Teresia Mumba; Shally Mahmoud; Abdalla Wesonga; Nana Mukuria; Tony Oduor; Evans Gichuru; Maarten F Schim van der Loeff; Shaun Palmer; Susan M Graham; Elise M van der Elst; Eduard J Sanders Journal: Open Forum Infect Dis Date: 2021-04-29 Impact factor: 3.835
Authors: Kelly A Curtis; Donna L Rudolph; Yi Pan; Kevin Delaney; Kathryn Anastos; Jack DeHovitz; Seble G Kassaye; Carl V Hanson; Audrey L French; Elizabeth Golub; Adaora A Adimora; Igho Ofotokun; Hector Bolivar; Mirjam-Colette Kempf; Philip J Peters; William M Switzer Journal: PLoS One Date: 2021-07-01 Impact factor: 3.240
Authors: Trevor A Crowell; Justin Ritz; Robert W Coombs; Lu Zheng; Joseph J Eron; John W Mellors; Joan Dragavon; Gert U van Zyl; Javier R Lama; Kiat Ruxrungtham; Beatriz Grinsztejn; Roberto C Arduino; Lawrence Fox; Jintanat Ananworanich; Eric S Daar Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 20.999